Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy D Shapiro

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Research and Practice in Thrombosis and Haemostasis|February 24, 2025
Recombinant factor VIIa: new insights into the mechanism of action through product innovationMiguel A Escobar, Maureane Hoffman, Giancarlo Castaman, et al.
Stem Cell Research|April 12, 2017
Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutationMuhammad Zeeshan Afzal, Melanie Gartz, Ekaterina A Klyachko, et al.
Blood|January 12, 2018
Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiencyAmy D Shapiro, Charles Nakar, Joseph M Parker, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 23, 2019
Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomesBeth Boulden Warren, Linda Jacobson, Christine Kempton, et al.
Transfusion|March 16, 2002
Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia BBruce M Ewenstein, J Heinrich Joist, Amy D Shapiro, et al.
Patient Preference and Adherence|October 17, 2017
Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) studyChristine L Kempton, Michael Wang, Michael Recht, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 31, 2019
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiencyJoline L Saes, Saskia E M Schols, Kathleen F Betbadal, et al.
Blood|December 11, 2012
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined CohortJan Astermark, Sharyne M Donfield, Edward D Gomperts, et al.
Circulation|June 8, 2017
Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac FibrosisPanagiotis Flevaris, Sadiya S Khan, Mesut Eren, et al.
The New England Journal of Medicine|September 9, 2020
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia ABarbara A Konkle, Amy D Shapiro, Doris V Quon, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Research and Practice in Thrombosis and Haemostasis|February 24, 2025
Recombinant factor VIIa: new insights into the mechanism of action through product innovationMiguel A Escobar, Maureane Hoffman, Giancarlo Castaman, et al.
Stem Cell Research|April 12, 2017
Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutationMuhammad Zeeshan Afzal, Melanie Gartz, Ekaterina A Klyachko, et al.
Blood|January 12, 2018
Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiencyAmy D Shapiro, Charles Nakar, Joseph M Parker, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 23, 2019
Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomesBeth Boulden Warren, Linda Jacobson, Christine Kempton, et al.
Transfusion|March 16, 2002
Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia BBruce M Ewenstein, J Heinrich Joist, Amy D Shapiro, et al.
Patient Preference and Adherence|October 17, 2017
Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) studyChristine L Kempton, Michael Wang, Michael Recht, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 31, 2019
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiencyJoline L Saes, Saskia E M Schols, Kathleen F Betbadal, et al.
Blood|December 11, 2012
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined CohortJan Astermark, Sharyne M Donfield, Edward D Gomperts, et al.
Circulation|June 8, 2017
Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac FibrosisPanagiotis Flevaris, Sadiya S Khan, Mesut Eren, et al.
The New England Journal of Medicine|September 9, 2020
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia ABarbara A Konkle, Amy D Shapiro, Doris V Quon, et al.
Pageof 8